Menu
Login

Report Library

All Reports

2014 Community-Acquired Pneumonia Pulse

December 18, 2014

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates. Topics covered in this survey include:
  • Current usage of antibiotics for CAP, grouped by antibiotic class.
  • Bacterial pathogens of greatest current concern in CAP.
  • Prescribing preferences following failure of 1st-line empiric CAP therapy.
  • Potential prescribing levels for CAP drugs with greater potency than existing (generic) drugs but higher price.
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

To purchase the community-acquired pneumonia survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Community Acquired Pneumonia (CAP) (Antibacterial)

 Additional Resources: